SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories informs about notice of board meeting and trading window closure

23 Sep 2024 Evaluate

Pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that a meeting of the Board of Directors of the Company will be held on Monday, 30th September, 2024, to consider, integration and consolidation of the generics formulations business in the US market of Bayshore Pharmaceuticals LLC (wholly owned step-down subsidiary) into Unichem Pharmaceuticals (USA) Inc. (wholly owned subsidiary of Company’s subsidiary) so as to consolidate all the Ipca Group’s USA generics formulations business under one entity. Pursuant to the Company’s Code of Conduct to Regulate, Monitor and Report Trading by Insiders, formulated and adopted under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in shares of the Company for designated persons, directors, insiders and their immediate relatives has been closed from Monday, 23rd September 2024 in view of the above meeting of the Board of Directors of the Company. The window closure will continue from 1st October 2024 till 48 hours after declaration of unaudited financial results of the Company for the 2nd quarter and half year ended 30th September 2024.

The above information is a part of company’s filings submitted to BSE.

Ipca Laboratories Share Price

1572.00 28.05 (1.82%)
06-May-2026 15:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.75
Dr. Reddys Lab 1307.35
Cipla 1365.25
Zydus Lifesciences 940.00
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×